Immatics N V (IMTX)

May 18, 2025

Immatics FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World

May 18, 2025

May 17, 2025

Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S - simplywall.st

May 17, 2025

May 16, 2025

The Manufacturers Life Insurance Company Sells 71,487 Shares of Immatics (NASDAQ:IMTX) - Defense World

May 16, 2025

May 14, 2025

Immatics: Q1 Earnings Snapshot - CT Insider

May 14, 2025

May 14, 2025

Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewswire

May 14, 2025

May 13, 2025

Immatics NV earnings missed by €0.07, revenue topped estimates - Investing.com South Africa

May 13, 2025

May 13, 2025

Immatics NV reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025

May 13, 2025

IMTX Sees Revenue Decline, Highlights Advances in Melanoma Thera - GuruFocus

May 13, 2025

May 13, 2025

Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs - TipRanks

May 13, 2025

May 13, 2025

Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025

May 11, 2025

Immatics (IMTX) Projected to Post Quarterly Earnings on Tuesday - Defense World

May 11, 2025

May 09, 2025

(IMTX) Proactive Strategies - news.stocktradersdaily.com

May 09, 2025

Apr 30, 2025

Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS) - The Business Journals

Apr 30, 2025

Apr 30, 2025

Guggenheim Capital LLC Takes $101,000 Position in Immatics (NASDAQ:IMTX) - Defense World

Apr 30, 2025

Apr 25, 2025

Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World

Apr 25, 2025

Apr 24, 2025

Are Immatics N.V (IMTX) shares a good deal now? - uspostnews.com

Apr 24, 2025

Apr 23, 2025

Immatics Announces Upcoming Oral and Poster Presentation on IMA2 - GuruFocus

Apr 23, 2025

Apr 23, 2025

Immatics N.V. to Present Updated Data on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - Nasdaq

Apr 23, 2025

Apr 23, 2025

Immatics Announces Upcoming Oral and Poster Presentation on - GlobeNewswire

Apr 23, 2025

Apr 23, 2025

Breakthrough Melanoma Treatment IMA203 : Phase 1b Results and Phase 3 Progress Coming to ASCO 2025 - Stock Titan

Apr 23, 2025

Apr 19, 2025

Short Interest in Immatics (NASDAQ:IMTX) Declines By 20.7% - Defense World

Apr 19, 2025

Apr 18, 2025

Immatics N.V (NASDAQ: IMTX): Moving Toward A Higher Share Price - Stocksregister

Apr 18, 2025

Apr 07, 2025

(IMTX) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 07, 2025

Apr 07, 2025

Immatics N.V (NASDAQ: IMTX): Can’t Stop The Stock’s Slide? - stocksregister.com

Apr 07, 2025

Apr 04, 2025

Immatics FY2025 EPS Estimate Lowered by Cantor Fitzgerald - The AM Reporter

Apr 04, 2025

Apr 04, 2025

FY2025 EPS Estimates for Immatics Decreased by Analyst - Defense World

Apr 04, 2025

Apr 02, 2025

Immatics (NASDAQ:IMTX) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World

Apr 02, 2025

Apr 02, 2025

Financial Contrast: Novonesis A/S (OTC:NVZMY) and Immatics (NASDAQ:IMTX) - Defense World

Apr 02, 2025

Apr 01, 2025

Research Analysts Set Expectations for Immatics Q1 Earnings - The AM Reporter

Apr 01, 2025

Mar 31, 2025

Q1 Earnings Estimate for Immatics Issued By Leerink Partnrs - Defense World

Mar 31, 2025

Mar 28, 2025

Immatics Reports Strong 2024 Financial Results and Progress - TipRanks

Mar 28, 2025

Mar 28, 2025

Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha

Mar 28, 2025

Mar 27, 2025

Immatics NV earnings beat by €0.74, revenue topped estimates - Investing.com

Mar 27, 2025

Mar 27, 2025

Immatics NV reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials - TipRanks

Mar 27, 2025

Mar 27, 2025

Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - Stock Titan

Mar 27, 2025

Mar 23, 2025

Immatics (NASDAQ:IMTX) Trading Down 5.3% – Time to Sell? - Defense World

Mar 23, 2025

Mar 17, 2025

IMMATICS N.V Earnings Preview: Recent $IMTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 17, 2025

Mar 17, 2025

(IMTX) Trading Report - Stock Traders Daily

Mar 17, 2025

Mar 13, 2025

Immatics (IMTX) Projected to Post Earnings on Thursday - Defense World

Mar 13, 2025

Mar 08, 2025

Short Interest in Immatics (NASDAQ:IMTX) Declines By 11.9% - Defense World

Mar 08, 2025

Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.

Mar 06, 2025

Mar 06, 2025

Y Intercept Hong Kong Ltd Buys New Position in Immatics (NASDAQ:IMTX) - Defense World

Mar 06, 2025

Mar 06, 2025

Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - Simply Wall St

Mar 06, 2025

Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire

Mar 06, 2025

Feb 21, 2025

Immatics N.V (IMTX) Recovers -2.54% From Low: Are We There Yet? - Stocks Register

Feb 21, 2025